D Heim
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen J, Löwenberg B, Manz M, Biemond B, Westerweel P, Klein S, Fehr M, Sinnige H, Efthymiou A, Legdeur M, Pabst T, Gregor M, van der Poel M, Deeren D, Tick L, Jongen-Lavrencic M, van Obbergh F, Boersma R, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele G. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia 2022; 36:2189-2195.
22.07.2022Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
22.07.2022Leukemia 2022; 36:2189-2195
Janssen J J W M, Löwenberg Bob, Manz M, Biemond B J, Westerweel P E, Klein S K, Fehr M, Sinnige H A M, Efthymiou Anna, Legdeur M C J C, Pabst T, Gregor M, van der Poel M W M, Deeren Dries, Tick L W, Jongen-Lavrencic Mojca, van Obbergh F, Boersma R S, de Weerdt Okke, Chalandon Yves, Heim D, Spertini Olivier, van Sluis G, Graux Carlos, Stüssi G, van Norden Y, Ossenkoppele G J
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
Miranda M, Neben K, Heinl C, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann W, Müller M, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Prümmer O, Fauser A, Verbeek W, Lauseker M, Kraus M, Proetel U, Hanfstein B, Fabarius A, Baerlocher G, Heim D, Hossfeld D, Kolb H, Krause S, Nerl C, Brümmendorf T, Saußele S. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia 2016; 30:1255-62.
09.02.2016Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
09.02.2016Leukemia 2016; 30:1255-62
Miranda M B, Neben K, Heinl Christina, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann W-K, Müller M C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Prümmer O, Fauser A A, Verbeek W, Lauseker M, Kraus M-P, Proetel U, Hanfstein B, Fabarius A, Baerlocher G M, Heim D, Hossfeld D K, Kolb H-J, Krause S W, Nerl C, Brümmendorf T H, Saußele S
Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98)
Zenhausern R, Rufener B, Bargetzi M, Leoncini L, Hess U, Meyer-Monard S, Heim D, Solenthaler M, Schmitz S, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leukemia & lymphoma 2009:1-11.
04.08.2009Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98)
04.08.2009Leukemia & lymphoma 2009:1-11
Zenhausern R, Rufener B, Bargetzi M, Leoncini L, Hess Urs, Meyer-Monard S, Heim D, Solenthaler M, Schmitz S-F Hsu, Tobler A